Suchergebnisse - "Remission Induction"

PubPharm (354)

71

Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysis

enthalten in: Rheumatology international | 2021

von Misra, D. | Rathore, U. | Patro, P. | +2

72

Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysis

enthalten in: Rheumatology international | 2021

von Misra, D. | Rathore, U. | Patro, P. | +2

73

Corticosteroid monotherapy for the management of Takayasu arteritis—a systematic review and meta-analysis

enthalten in: Rheumatology international | 2021

von Misra, D. | Rathore, U. | Patro, P. | +2

74

A study of volasertib in combination with low-dose cytarabine in patientsaged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study ofintravenous volasertib in combination with subcutaneous low-dosecytarabine vs. placebo + low-dose cytarabine in patients >= 65 years withpreviously untreated acute myeloid leukaemia, who are ineligible forintensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

75

A study of volasertib in combination with low-dose cytarabine in patientsaged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study ofintravenous volasertib in combination with subcutaneous low-dosecytarabine vs. placebo + low-dose cytarabine in patients >= 65 years withpreviously untreated acute myeloid leukaemia, who are ineligible forintensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

76

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

77

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

78

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

79

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021

80

A study of volasertib in combination with low-dose cytarabine in patients aged 65 years and above with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy : A phase III randomised, double-blind, controlled, parallel group study of intravenous volasertib in combination with subcutaneous low-dose cytarabine vs. placebo + low-dose cytarabine in patients = 65 years with previously untreated acute myeloid leukaemia, who are ineligible for intensive remission induction therapy. - POLO-AML-2

enthalten in: WHO International Clinical Trials Registry Platform | 2021